The Effects of Brotizolam, a New Hypnotic, on Cardiac and Respiratory Function in Volunteers

Cohn, Martin A.

doi:10.1159/000194631

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Opposing results, again present both in healthy subjects and patients with COPD, are available from a comparable amount of other studies 120,121,123,124,126,129,133,137,138,140 (Tables 2 and 3). These studies also focused on the respiratory effects of hypnotics (using alprazolam, brotizolam, diazepam, midazolam, flunitrazepam, flurazepam, nitrazepam, zaleplon, zolpidem and zopiclone), but could not find any adverse effects.…”

Section: Article In Pressmentioning

confidence: 60%

“…120 Most, but not all studies were performed during sleep. Medications studied included alprazolam, 115 brotizolam, 121 diazepam, [122][123][124][125][126] estazolam, 127 flurazepam, [127][128][129][130] flunitrazepam, 102,[131][132][133] lorazepam, 134 midazolam, 124 nitrazepam, 133,135 temazepam, 120 triazolam, 102,131,132,[136][137][138] zaleplon, 139 zolpidem 123,131,132,137,[139][140][141][142][143] and zopiclone. 122,125,144 Some of these studies (using diazepam, flunitrazepam, flurazepam, lorazepam, nitrazepam, triazolam, zolpidem and zopiclone) found that these drugs decrease central respiratory drive, increase upper airway resistance, particularly by acting on upper airway dilators (genioglossus muscles), decrease the arousal response, decrease respiratory muscle strength, and increase sleep-disordered breathing.…”

Section: Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Sleep, hypnotics and chronic obstructive pulmonary disease

Stege

Vos

Elshout

et al. 2008

Respiratory Medicine

View full text Add to dashboard Cite

The quality of sleep is significantly compromised in many patients with chronic obstructive pulmonary disease (COPD) and may be further diminished when certain comorbidities are present. A reduced sleep quality is associated with daytime consequences like fatigue, psychiatric problems and an impaired quality of life. Sleep induces physiologic alterations in respiratory function, which can become pathologic and may provoke or worsen hypoxemia and hypercapnia in COPD. Dyspnea, cough and excessive mucus production should be optimised to minimise causes for sleep disturbance. Pharmacological therapy may be helpful; sedatives like benzodiazepines and non-benzodiazepine benzodiazepine-receptor agonists (NBBRAs) are (equally) effective in improving sleep quality. Whether or not these hypnotics produce serious adverse respiratory effects during sleep, remains unclear due to opposing studies. Therefore, their use should be as short as possible.

show abstract

Section: Article In Pressmentioning

confidence: 60%

Section: Adverse Effectsmentioning

confidence: 99%

Sleep, hypnotics and chronic obstructive pulmonary disease

Stege

Vos

Elshout

et al. 2008

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

Safety of brotizolam in hospitalized patients

Lavon

Bejel

2018

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Brotizolam

Langley¹,

Clissold²

1988

Drugs

View full text Add to dashboard Cite

Brotizolam is a new thienotriazolodiazepine derivative with a pharmacological profile similar to that of benzodiazepines. It is indicated for use as an hypnotic in the management of insomnia, although it also has anticonvulsant, antianxiety and muscle relaxant properties in animals. In clinical trials brotizolam 0.125 to 0.5mg improved sleep in insomniacs similarly to nitrazepam 2.5 and 5mg, flunitrazepam 2mg and triazolam 0.25mg, whilst brotizolam 0.5mg was shown to be superior to flurazepam 30mg in some studies. Brotizolam is an effective hypnotic for hospital patients awaiting surgery, in whom it also reduces anxiety. Brotizolam has an elimination half-life of about 5 hours, which is 'intermediate' compared with the shorter-acting hypnotic, triazolam, and longer-acting benzodiazepines. Consequently, it is able to induce sleep without producing early morning rebound insomnia, and can also maintain sleep throughout the night. Brotizolam at dosages below 0.5mg at night usually produced minimal morning drowsiness; no residual impairment of psychomotor performance occurs following dosages within the recommended range of 0.125 to 0.25 mg/kg. No serious side effects have been reported to date and the most frequently observed adverse experiences are drowsiness, headache and dizziness. Mild rebound insomnia may occur in some patients when treatment is stopped. Thus, brotizolam is a useful hypnotic which can be used in patients who have difficulty in falling asleep and also in patients who are troubled by night-time awakenings. Used in the recommended dosage it may be particularly useful for patients in whom daytime impairment of performance is unacceptable.

show abstract

The Effects of Brotizolam, a New Hypnotic, on Cardiac and Respiratory Function in Volunteers

Cited by 3 publications

References 6 publications

Sleep, hypnotics and chronic obstructive pulmonary disease

Sleep, hypnotics and chronic obstructive pulmonary disease

Safety of brotizolam in hospitalized patients

Brotizolam

Contact Info

Product

Resources

About